Shares

6 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2018

Feb 14, 2019

SELL
$11.63 - $32.67 $13.3 Million - $37.5 Million
-1,146,636 Closed
0 $0
Q3 2018

Nov 14, 2018

BUY
$29.37 - $49.48 $5,874 - $9,896
200 Added 0.02%
1,146,636 $33.7 Million
Q2 2018

Aug 14, 2018

SELL
$42.06 - $62.4 $817,982 - $1.21 Million
-19,448 Reduced 1.67%
1,146,436 $52.1 Million
Q1 2018

May 15, 2018

BUY
$50.12 - $67.72 $3.16 Million - $4.27 Million
63,000 Added 5.71%
1,165,884 $61.6 Million
Q4 2017

Feb 14, 2018

BUY
$57.69 - $84.58 $18.3 Million - $26.8 Million
317,184 Added 40.37%
1,102,884 $75 Million
Q3 2017

Nov 14, 2017

BUY
$67.17 - $84.81 $52.8 Million - $66.6 Million
785,700
785,700 $64.7 Million

Others Institutions Holding CLVS

# of Institutions
1
Shares Held
166
Call Options Held
0
Put Options Held
0

About Clovis Oncology, Inc.


  • Ticker CLVS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 144,480,000
  • Market Cap $13M
  • Description
  • Clovis Oncology, Inc., a biopharmaceutical company, focuses on acquiring, developing, and commercializing anti-cancer agents in the United States, Europe, and internationally. In the U.S., the company offers Rubraca (rucaparib), an oral small molecule inhibitor of poly ADP-ribose polymerase for recurrent epithelial ovarian, fallopian tube, or pr...
More about CLVS
Track This Portfolio

Track Avoro Capital Advisors LLC Portfolio

Follow Avoro Capital Advisors LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Avoro Capital Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Avoro Capital Advisors LLC with notifications on news.